SARS-CoV-2 Reinfection Rate: A Systematic Review and Meta-analysis

Document Type : Systematic Review

Authors
Y. Alimohamadi 1
K. Bahani 2
K. Alimohammadi 1
M. Sepandi 1
1 Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Department of Epidemiology and Biostatistics School of public health, Tehran University of Medical Science, Tehran, Iran
10.52547/iem.9.1.63
Abstract
Backgrounds: Reinfection among COVID-19 patients is still a challenging issue in the medical literature. Therefore, the current meta-analysis was conducted to estimate the pooled incidence rate of reinfection among COVID-19 patients.

Materials & Methods: A comprehensive search was conducted in PubMed, Web of Science, and Scopus databases from July 1 to October 1, 2021. Original studies which estimated the incidence rate of COVID-19 reinfection were included. CASP (Critical Appraisal skills program) was used to assess the quality of studies. Data were analyzed by STATA statistical software Version 15 (StataCorp, College Station, TX, USA).

Findings: A total of 3803 articles were found, of which 16 articles remained after title, abstract, and full text screening. The minimum and maximum incidence rates of reinfection were 0.001 and 0.73%, respectively. The pooled estimated incidence rate of COVID-19 reinfection was 0.11% (95% confidence interval: 0.02-0.20, p< .001, I2 = 100.0). The highest pooled estimated incidence rate of reinfection was observed in people <50 years old (0.14%) (95% CI: 0.001-0.34, p<.001, I2 = 100). Regarding the time elapsed after the first infection, the highest reinfection rate occurred four months after the first infection (0.12%) (95% CI: 0.001-0.27, p< .001, I2 = 100).

Conclusion: The incidence rate of reinfection among COVID-19 patients is expected to be high. However, it seems that the influence of factors including the age of patients and the time elapsed after the first infection must be considered.

Keywords

1. Tang JW, Tambyah PA, Hui DS. Emergence of a novel coronavirus causing respiratory illness from Wuhan, China. Journal of infection. 2020;80(3):350-71.
2. Perlman S. Another decade, another coronavirus. Mass Medical Soc; 2020. p. 760-2.
3. Nobel YR, Phipps M, Zucker J, Lebwohl B, Wang TC, Sobieszczyk ME, et al. Gastrointestinal symptoms and coronavirus disease 2019: a case-control study from the United States. Gastroenterology. 2020;159(1):373-5. e2.
4. Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID‐19: A systematic review and meta‐analysis. Journal of medical virology. 2022;94(1):44-53.
5. Alimohamadi Y, Sepandi M. Basic reproduction number: An important indicator for the future of the COVID-19 epidemic in Iran. Journal of Military Medicine. 2020;22(1):96-7.
6. Afrashteh S, Alimohamadi Y, Sepandi M. The role of isolation, quarantine and social distancing in controlling the COVID-19 epidemic. Journal of Military Medicine. 2020;22(2):210-1.
7. Malkov E. Simulation of coronavirus disease 2019 (COVID-19) scenarios with possibility of reinfection. Chaos, Solitons & Fractals. 2020;139:110296.
8. What C. Reinfections and COVID-19.
9. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Nature Publishing Group; 2020. p. 1451-4.
10. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. BioRxiv. 2020:2020.03. 13.990226.
11. McAuley AJ, Kuiper MJ, Durr PA, Bruce MP, Barr J, Todd S, et al. Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. npj Vaccines. 2020;5(1):96.
12. An J, Liao X, Xiao T, Qian S, Yuan J, Ye H, et al. Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test. Annals of translational medicine. 2020;8(17).
13. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJ, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet. 2021;397(10283):1459-69.
14. Felix HC, Seaberg B, Bursac Z, Thostenson J, Stewart MK. Why do patients keep coming back? Results of a readmitted patient survey. Social work in health care. 2015;54(1):1-15.
15. Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U, Widyaningrum D, et al. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Scientific reports. 2020;10(1):20692.
16. Lu J, Peng J, Xiong Q, Liu Z, Lin H, Tan X, et al. Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. EBioMedicine. 2020;59:102960.
17. Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection. medRxiv. 2020.
18. Pal R, Banerjee M. Are people with uncontrolled diabetes mellitus at high risk of reinfections with COVID-19? Primary care diabetes. 2021;15(1):18-20.
19. Akinbami LJ, Biggerstaff BJ, Chan PA, McGibbon E, Pathela P, Petersen LR. Reinfection with severe acute respiratory syndrome coronavirus 2 among previously infected healthcare personnel and first responders. Clinical Infectious Diseases. 2022;75(1):e201-e7.
20. Jeffery-Smith A, Iyanger N, Williams SV, Chow JY, Aiano F, Hoschler K, et al. Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020. Eurosurveillance. 2021;26(5):2100092.
21. Lumley S, O’Donnell D, Stoesser N, Matthews P, Howarth A, Hatch S, et al. Oxford University Hospitals Staff Testing Group. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384(6):533-40.
22. Perez G, Banon T, Gazit S, Moshe SB, Wortsman J, Grupel D, et al. A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report. MedRxiv. 2021:2021.03. 06.21253051.
23. Pilz S, Chakeri A, Ioannidis JP, Richter L, Theiler‐Schwetz V, Trummer C, et al. SARS‐CoV‐2 re‐infection risk in Austria. European journal of clinical investigation. 2021;51(4):e13520.
24. Hussein NR, Rashad BH, Almizori LA, Yousif SS, Sadeeq AT, Abdulkareem YR, et al. The risk of SARS-CoV-2 reinfection in Duhok city, Kurdistan region of Iraq. Mediterranean journal of hematology and infectious diseases. 2021;13(1).
25. Peltan ID, Beesley SJ, Webb BJ, Lopansri BK, Sinclair W, Jacobs JR, et al. Evaluation of potential COVID-19 recurrence in patients with late repeat positive SARS-CoV-2 testing. PLoS One. 2021;16(5):e0251214.
26. Qureshi AI, Baskett WI, Huang W, Lobanova I, Hasan Naqvi S, Shyu C-R. Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients undergoing serial laboratory testing. Clinical Infectious Diseases. 2022;74(2):294-300.
27. Rennert L, McMahan C. Risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in a university student population. Clinical Infectious Diseases. 2022;74(4):719-22.
28. Zare F, Teimouri M, Khosravi A, Rohani-Rasaf M, Chaman R, Hosseinzadeh A, et al. COVID-19 re-infection in Shahroud, Iran: a follow-up study. Epidemiology & Infection. 2021;149.
29. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection rates among patients who previously tested positive for coronavirus disease 2019: a retrospective cohort study. Clinical Infectious Diseases. 2021;73(10):1882-6.
30. Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, et al. SARS-CoV-2 reinfection rate and estimated effectiveness of the inactivated whole virion vaccine BBV152 against reinfection among health care workers in New Delhi, India. JAMA network open. 2022;5(1):e2142210-e.
31. SeyedAlinaghi S, Oliaei S, Kianzad S, Afsahi AM, MohsseniPour M, Barzegary A, et al. Reinfection risk of novel coronavirus (COVID-19): a systematic‎ review of current evidence. World journal of virology. 2020;9(5):79.
32. Dhillon RA, Qamar MA, Gilani JA, Irfan O, Waqar U, Sajid MI, et al. The mystery of COVID-19 reinfections: A global systematic review and meta-analysis. Annals of Medicine and Surgery. 2021;72:103130.
33. Quarleri J, Galvan V, Delpino MV. Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load. GeroScience. 2022;44(1):53-6.
34. Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Frontiers in microbiology. 2019;10:2752.
35. Chen L, Liu H, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases. 2020;43:E005-E.
36. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227-30.
37. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B, Wollants E. & Maes, P.(2020). Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis.10.
38. Iwasaki A. What reinfections mean for COVID-19. The Lancet infectious diseases. 2021;21(1):3-5.
39. Arafkas M, Khosrawipour T, Kocbach P, Zielinski K, Schubert J, Mikolajczyk A, et al. Current meta‐analysis does not support the possibility of COVID‐19 reinfections. Journal of medical virology. 2021;93(3):1599-604.
40. Ren X, Ren X, Lou J, Wang Y, Huang Q, Shi Y, et al. A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR. EClinicalMedicine. 2021;34:100839.
41. Chivese T, Matizanadzo JT, Musa OA, Hindy G, Furuya-Kanamori L, Islam N, et al. The prevalence of adaptive immunity to COVID-19 and reinfection after recovery–a comprehensive systematic review and meta-analysis. Pathogens and Global Health. 2022;116(5):269-81.
42. Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. Infectious Diseases. 2021;53(5):315-24.
43. Murillo-Zamora E, Mendoza-Cano O, Delgado-Enciso I, Hernandez-Suarez CM. Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection. Public Health. 2021;193:113-5.
44. Racine É, Boivin G, Longtin Y, McCormack D, Decaluwe H, Savard P, et al. The REinfection in COVID‐19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers. Influenza and Other Respiratory Viruses. 2022;16(5):916-25.
45. Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling M-J, et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021;71:103561.
46. Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA, Younuskunju S, et al. Assessment of the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection in an intense reexposure setting. Clinical Infectious Diseases. 2021;73(7):e1830-e40.
47. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. The lancet. 2021;397(10280):1204-12.
48. Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, et al. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clinical Microbiology and Infection. 2021;27(3):315-8.
49. Costa AOC, de Carvalho Aragão Neto H, Lopes Nunes AP, Dias de Castro R, Nóbrega de Almeida R. COVID-19: Is reinfection possible? EXCLI journal. 2021;20:522-36.
Infection Epidemiology and Microbiology
Volume 9, Issue 1
March 2023
Pages 63-70